Compatibility of amiodarone hydrochloride with vasopressin during simulated Y-site administration.
The objective of this study was to determine the compatibility of amiodarone hydrochloride with vasopressin during simulated Y-site administration. Amiodarone hydrochloride is compatible with vasopressin under simulated-use conditions when administered according to the Advanced Cardiac Life Support Guidelines. A simulated-use approach is a more appropriate way to evaluate compatibility of drug solutions and to assure safe and adequate drug delivery to the patient, particularly when the drug being evaluated is well-documented to have physical or chemical incompatibility concerns with various drugs. When amiodarone hydrochloride (50 mg/mL) was diluted to 6 mg/mL with 5% dextrose injection, then mixed with an equal volume of vasopressin (0.2 units/mL in normal saline) in a glass test tube, no visual incompatibility was observed for up to 24 hours. The purpose of our study was to assess compatibility of the two drugs under simulated-use conditions and to measure the recovery of amiodarone by high-performance liquid chromatography after sequential administration of vasopressin and amiodarone hydrochloride according to the Advanced Cardiac Life Support Guidelines.
Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University, Hampton, VA 23668, USA.
Corinne C
CC
Ramaley
Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University, Hampton, VA 23668, USA.
Feng
F
Li
Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University, Hampton, VA 23668, USA.
Chengan
C
Du
D000638:Amiodarone / Q000008:administration & dosage / Q000737:chemistry*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid; D004338:Drug Combinations; D004339:Drug Compounding / Q000379:methods*; D004344:Drug Incompatibility; D004355:Drug Stability; D004356:Drug Storage; D005947:Glucose / Q000737:chemistry; D006801:Humans; D007275:Injections, Intravenous; D017410:Practice Guidelines as Topic; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000737:chemistry; D014667:Vasopressins / Q000008:administration & dosage / Q000737:chemistry*
D000889:Anti-Arrhythmia Agents; D004338:Drug Combinations; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D005947:Glucose; D000638:Amiodarone